Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies.

Frazzi R, Auffray C, Ferrari A, Filippini P, Rutella S, Cesario A.

J Transl Med. 2016 Sep 1;14:252. doi: 10.1186/s12967-016-1018-2. Review.

2.

Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models.

Fernández-Santiago R, Ezquerra M.

Stem Cells Int. 2016;2016:9464591. doi: 10.1155/2016/9464591. Review.

3.

Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.

Andreoli F, Del Rio A.

Comput Struct Biotechnol J. 2015 May 7;13:358-65. doi: 10.1016/j.csbj.2015.04.007. Review.

4.

Skewed Epigenetics: An Alternative Therapeutic Option for Diabetes Complications.

Togliatto G, Dentelli P, Brizzi MF.

J Diabetes Res. 2015;2015:373708. doi: 10.1155/2015/373708. Review.

5.

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus.

Lotfy M, Kalasz H, Szalai G, Singh J, Adeghate E.

Open Med Chem J. 2014 Dec 31;8:28-35. doi: 10.2174/1874104501408010028.

6.

Synthesis of novel derivatives of 5-hydroxymethylcytosine and 5-formylcytosine as tools for epigenetics.

Chentsova A, Kapourani E, Giannis A.

Beilstein J Org Chem. 2014 Jan 3;10:7-11. doi: 10.3762/bjoc.10.2.

7.

Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets.

Lizcano F, Garcia J.

Pharmaceuticals (Basel). 2012 Sep 12;5(9):963-90. doi: 10.3390/ph5090963.

8.

Strategies to modulate heritable epigenetic defects in cellular machinery: lessons from nature.

Pandian GN, Sugiyama H.

Pharmaceuticals (Basel). 2012 Dec 27;6(1):1-24. doi: 10.3390/ph6010001.

9.
10.

Epigenetics advancing personalized nanomedicine in cancer therapy.

Liu S.

Adv Drug Deliv Rev. 2012 Oct;64(13):1532-43. doi: 10.1016/j.addr.2012.08.004. Review.

11.

Epigenetics and miRNA emerge as key regulators of smooth muscle cell phenotype and function.

Clifford RL, Singer CA, John AE.

Pulm Pharmacol Ther. 2013 Feb;26(1):75-85. doi: 10.1016/j.pupt.2012.07.002. Review.

12.

Epigenetic inheritance of disease and disease risk.

Bohacek J, Mansuy IM.

Neuropsychopharmacology. 2013 Jan;38(1):220-36. doi: 10.1038/npp.2012.110. Review.

13.

HEMD: an integrated tool of human epigenetic enzymes and chemical modulators for therapeutics.

Huang Z, Jiang H, Liu X, Chen Y, Wong J, Wang Q, Huang W, Shi T, Zhang J.

PLoS One. 2012;7(6):e39917. doi: 10.1371/journal.pone.0039917.

14.
15.

Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.

Ramos EA, Grochoski M, Braun-Prado K, Seniski GG, Cavalli IJ, Ribeiro EM, Camargo AA, Costa FF, Klassen G.

PLoS One. 2011;6(12):e29461. doi: 10.1371/journal.pone.0029461.

Items per page

Supplemental Content

Support Center